This formulation combines four distinct peptides GHK-Cu , BPC-157 , TB-500 , and KPV into a single lyophilized preparation for use in controlled laboratory applications
These may include: Muscle cramps or weakness Increased heart rate Seizures in individuals with seizure disorders Worsening of hypothyroid symptoms Gastrointestinal discomfort in sensitive individuals If any of these symptoms occur, its important to discontinue use and seek medical advice immediately
Quick response from physician, thorough
For data integrity, it would be safest to discard the vial
doi: 10.3389/fphar.2024.1419844 Received 19 April 2024 Accepted 29 May 2024 Published 19 June 2024 Volume 15 - 2024 Edited by Yi Wu, Nanjing Agricultural University, China Reviewed by Lei Li, China Agricultural University, China Adelijiang Wusiman, Xinjiang Agricultural University, China Wenjing Sun, Yulin Normal University, China Weijie Lv, South China Agricultural University, China Updates Copyright 2024 Li, Wang, Qu, Ahmed, Enneb, Obeidat, Liu, Dessie, Kim, Adam and Cai